Skip Navigation


NDT Advance Access originally published online on October 4, 2005
Nephrology Dialysis Transplantation 2005 20(12):2824-2826; doi:10.1093/ndt/gfi180
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
20/12/2824    most recent
gfi180v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Chin, G.
Right arrow Articles by Harvey, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chin, G.
Right arrow Articles by Harvey, J. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2005]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Case Report

Infliximab and nephrotic syndrome

George Chin1, Grant Luxton1 and Jennet M. Harvey2

1 Renal Unit, Sir Charles Gairdner Hospital, Nedlands and 2 Department of Pathology, University of Western Australia and PathCentre, Western Australia, Australia

Correspondence and offprint requests to: Dr George Chin, Department of Nephrology, Derriford Hospital NHS Trust, Derriford, Plymouth, Devon PL6 8DH, UK. Email: george.chin{at}phnt.swest.nhs.uk

Infliximab is a chimeric tumor necrosis factor-alpha (TNF-{alpha}) monoclonal antibody, which has been used extensively in patients with rheumatoid arthritis and inflammatory bowel disease. It also appears to be effective in other conditions such as psoriasis and ankylosing spondylitis. The major side effect of infliximab is infection. Renal complications are uncommon and not well recognized. This report describes a probable case of infliximab-induced membranous nephropathy.

Keywords: drug-induced; infliximab; nephrotic syndrome


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann Rheum DisHome page
A. J Hueber, A. Tunc, G. Schett, and B. Manger
Anti-tumour necrosis factor {alpha} therapy in patients with impaired renal function
Ann Rheum Dis, July 1, 2007; 66(7): 981 - 982.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.